http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2010108499-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0806 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0817 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-001 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K4-00 |
| filingDate | 2008-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2010108499-A |
| titleOfInvention | DIRECTED PEPTIDES ON VEGFR-1 / NRP-1 |
| abstract | 1. A peptide of 10 amino acids or smaller, comprising at least the continuous amino acid sequence of Leu Pro Arg. ! 2. The peptide according to claim 1, where the specified peptide consists of 7 amino acids or less or 5 amino acids or less. ! 3. The peptide according to claim 1, further characterized as comprising Cys Leu Pro Arg Cys (SEQ ID NO: 1). ! 4. The peptide according to claim 3, further characterized as a cyclic peptide. ! 5. The peptide according to claim 1, where the peptide consists of the sequence Leu Pro Arg or D (Leu Pro Arg). ! 6. The peptide according to claim 1, further characterized as comprising one or more D-amino acids. ! 7. The peptide according to any one of claims 1 to 6, where the specified peptide is attached to! (a) a protein, and the peptide is conjugated to a protein to form a protein conjugate; or ! (b) a molecule that is a drug, chemotherapeutic agent, diagnostic agent, radioisotope, pro-apoptotic agent, anti-angiogenic agent, hormone, cytokine, growth factor, cytotoxic agent, peptide, protein, antibiotic, antibody or its fragment or single-chain antibody , an imaging agent, a survival factor, an anti-apoptotic agent, a hormone antagonist, or an antigen. ! 8. The peptide according to claim 7, where the specified molecule is! (a) a pro-apoptotic agent selected from the group consisting of gramicidin; magainin; mellitin; defensin; cecropin; (KLAKLAK) 2 (SEQ ID NO: 2); (KLAKKLA) 2 (SEQ ID NO: 3); (KAAKKAA) 2 (SEQ ID NO: 4); (KLGKKLG) 3 (SEQ ID NO: 5); Bcl-2; Bad Bak; Bax and Bik; or ! (b) an anti-angiogenic agent selected from the group consisting of thrombospondin, angiostatin, pigment epithelium factor, angiotensin, laminin peptides, fibronectin peptides, activator inhibitors p� |
| priorityDate | 2007-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 470.